Skip to Content
Merck

Skip To

G0798

Sigma-Aldrich

GSK1016790A

≥98% (HPLC), solid, TRPV4 channel agonist

Synonym(s):

GSK101, (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide

Sign Into View Organizational & Contract Pricing

Select a Size

Change View
1 G
₹15,800.00

About This Item

Empirical Formula (Hill Notation):
C28H32Cl2N4O6S2
CAS Number:
Molecular Weight:
655.61
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

₹15,800.00


Please contact Customer Service for Availability

Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

GSK1016790A, ≥98% (HPLC)

Quality Level

Assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

storage temp.

−20°C

SMILES string

CC(C)C[C@H](NC(=O)c1cc2ccccc2s1)C(=O)N3CCN(CC3)C(=O)[C@H](CO)NS(=O)(=O)c4ccc(Cl)cc4Cl

InChI

1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML0803SML1804S5701
VUF10661 ≥98% (HPLC)

SML0803

VUF10661

AM4113 ≥98% (HPLC)

SML1804

AM4113

SR 49059 ≥97% (HPLC)

S5701

SR 49059

form

solid

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥97% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >10 mg/mL

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear (warmed)

solubility

DMSO: ≥10 mg/mL

originator

GlaxoSmithKline

originator

-

originator

-

originator

Sanofi Aventis

Application

GSK1016790A has been used:
  • to stimulate transient receptor potential vanilloid 4 (TRPV4)-mediated currents in Xenopus laevis oocytes[1]
  • to stimulate cells in Ca2+ level measurement in human retinal capillary endothelial cells (HRCECs)[2]
  • to study the role of TRPV4 channels in brain injury after intracerebral hemorrhage (ICH)[3]
  • to trigger the opening of TRPV4 channels in bovine nucleus pulposus cells or Hanks′ Balanced Salt Solution[4]

Biochem/physiol Actions

GSK1016790A is a novel and potent TRPV4 channel agonist.
GSK1016790A is a novel and potent TRPV4 channel agonist. The TRPV4 (transient receptor potential vanilloid 4) member of the TRP superfamily has been implicated in numerous physiological processes. GSK1016790A elicited Ca2+ influx in mouse and human TRPV4 expressing HEK cells (EC50 values of 18 and 2.1 nM, respectively), and evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM. It is 300 fold more potent than 4a-PDD (Cat. No. P8014).

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


  • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
    Manier S
    Leukemia, 31(4), 853-860 (2017)
    Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
    Lewis KM
    Lung Cancer, 90(2), 182-190 (2015)
    STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.
    Pedroza M
    Faseb Journal, 30(1), 129-140 (2016)
    Mesias Pedroza et al.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(1), 129-140 (2015-09-02)
    Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is a key step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF-β, the
    Curtis A Clark et al.
    Cancer research, 76(23), 6964-6974 (2016-09-28)
    PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service